Europe
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. FDA, which will speed up the regulatory process for these medications.
There was plenty of clinical trial updates last week. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.
Although August is a fairly busy month for PDUFA dates, there were only two on the U.S. FDA’s calendar for this week, and one of those has already been reported. Here’s a look.
It was a busy week for clinical trial announcements. Take a look.
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES